Director’s Bold Move: Massive Stock Purchase in Zomedica!

New insider activity at Zomedica ( (ZOMDF) ) has taken place on May 21, 2025.

Director Johnny Powers has made a significant move by purchasing 500,000 shares of Zomedica stock, with the transaction valued at $20,000.

Recent Updates on ZOMDF stock

Zomedica Corp. recently reported its Q1 2025 earnings, highlighting a 4% revenue increase to $6.5 million, driven by strong demand for its PulseVet and TRUFORMA product lines and the launch of VETIGEL. Despite a 25% decline in diagnostics revenue due to the absence of large initial distribution orders for VetGuardian products, the company maintained a robust gross margin of 68% and a liquidity position of $65 million. Operating expenses were reduced by 9%, but the adjusted non-GAAP EBITDA loss increased slightly to $5.7 million, reflecting ongoing investments. The resignation of CFO Scott Jordan added to the company’s challenges, with Michael Zuehlke stepping in temporarily. Analysts noted mixed financial performance with revenue growth but persistent profitability challenges, weak momentum, and valuation concerns due to a negative P/E ratio. Despite these issues, Zomedica’s management remains optimistic about future growth prospects.

Spark’s Take on ZOMDF Stock

According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.

Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.

To see Spark’s full report on ZOMDF stock, click here.

More about Zomedica

YTD Price Performance: -66.43%

Average Trading Volume: 6,092,882

Technical Sentiment Signal: Strong Sell

Current Market Cap: $46.06M